- (2011) Volume 12, Issue 6
Neal C Patel1, William C Palmer2, Murli Krishna3, Michele D Lewis4, Michael B Wallace4
1Department of Gastroenterology and Hepatology, Mayo Clinic Arizona. Scottsdale, AZ, USA
Departments of 2Internal Medicine, 3Pathology, and 4Gastroenterology and Hepatology, Mayo Clinic Florida. Jacksonville, FL, USA
Received October 8th, 2011- Accepted October 18th, 2011
Herpesvirus 3, Human; Herpes Zoster; Immunization; Pancreatitis
Dear Sir:
Autoimmune pancreatitis is a form of chronic pancreatitis that was first described by Sarles et al. in 1961, and later coined in 1995 by Yoshida et al. [1, 2]. Subsequently, two types of autoimmune pancreatitis have been described. Autoimmune pancreatitis type 1 fits the classic description of the disease and is associated with a lymphoplasmacytic sclerosing pancreatitis and an elevated level of immunoglobulin G4 subclass of IgG. Autoimmune pancreatitis type 2 is characterized by a distinct neutrophilic obliterating lesion of the ductal epithelium [3]. Although the histopathological findings of autoimmune pancreatitis are well studied, the risk factors, pathogenesis, and treatments are still not well understood. There have been many hypotheses to the etiology of autoimmune pancreatitis, which are still being studied. One proposed theory is that of microbial mimicry leading to an autoimmune disorder. Several studies have been conducted to evaluate for a link with autoimmune pancreatitis and infectious causes, such as Helicobacter Pylori, without identifying a clear relationship [4]. Additionally, there has been a reported link between viral infections and acute pancreatitis, such as Coxackievirus [5].
Beginning several months ago, some of the physicians of our Department of Gastroenterology noticed a general pattern of newly diagnosed autoimmune pancreatitis with recent shingles outbreak or Zoster vaccine administration. To further study the possible association, we conducted a pilot study to examine the incidence of autoimmune pancreatitis with concomitant Varicella Zoster Virus. We identified four patients from the Mayo Clinic Medical Data Trust who had undergone core biopsy or surgical resection of the pancreas and had been diagnosed with autoimmune pancreatitis. All cases of autoimmune pancreatitis were associated with an elevated (more than 1.5 x upper reference limit) IgG4 level as well as histologic changes consistent with the diagnosis. With these four cases of autoimmune pancreatitis identified, we identified two cases for controls with normal pancreatic tissue. Both of these groups of tissue samples had already been collected and were accessed from the Mayo Medical Laboratory. Once the six tissue samples were obtained, we conducted in-situ hybridization assays for Varicella Zoster Virus. We used this technique because it enables localization of the viral DNA in the tissues if present. Finally, we calculated the incidence of Varicella Zoster Virus antibodies in normal pancreatic tissue and in autoimmune pancreatitis tissue samples. Out of the four cases of confirmed autoimmune pancreatitis, zero tissue samples showed evidence of concomitant Varicella Zoster Virus on in-situ hybridization assays. Positive controls for Varicella Zoster Virus in-situ hybridization were used (Figure 1). Autoimmune pancreatitis is a disease process with many aspects which are still not well understood due to its relatively low incidence. Although we noted an anecdotal association between exposure to Varicella Zoster Virus and onset of autoimmune pancreatitis, we were unable to identify any evidence to support a link between these events. Specifically, none of our tissue samples diagnosed with autoimmune pancreatitis based on histology and elevated serum IgG4 levels had a positive in-situ hybridization assay for Varicella Zoster Virus.
Figure 1. Tissue sample of a positive control for Varicella Zoster Virus in-situ hybridization.
Funding for this project was provided as an unrestricted educational support for fellow research from the TAP Pharmaceutical (Deerfield, IL, USA)
We have no conflicts on interest to disclose
